Sponsor: Cancer Insight, LLC
Enrolling in our Bronx locations. This is a multi-center, prospective, randomized, single-blinded, placebo-controlled phase II trial of trastuzumab + nelipepimut-S/GM-CSF versus trastuzumab + GM-CSF alone. For patients with HER2 positive breast cancer.